FDA Approves Opus Genetics Treatment for Age-Related Near Vision Impairment

Key Facts

The U.S. Food and Drug Administration approved Opus Genetics' supplemental New Drug Application for phentolamine ophthalmic solution 0.75% to treat age-related near vision impairment in adults. GlobeNewswire reported that the approval was supported by positive data from pivotal Phase 3 VEGA-2 and VEGA-3 clinical trials, which met their primary and key secondary efficacy endpoints with no treatment-related serious adverse events.

IRD closed at $4.05 on October 15, 2026, after reaching a day high of $4.28 and a low of $3.98. The regulatory milestone expands the addressable market for the clinical-stage biotech company, as the approved solution functions as an adrenergic antagonist designed to reduce pupil size and improve near vision.